Q3 2023 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2023-11-14 · accession 0001214659-23-014945
$679.1M
Reported value
26
Positions
2023-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $75.8M | 11.2% | 1,502,747 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $54.9M | 8.08% | 5,631,042 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $49.6M | 7.30% | 23,375,839 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $43.1M | 6.34% | 2,678,209 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC. | $37.8M | 5.57% | 10,000,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES, INC. | $35.1M | 5.17% | 11,111,111 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS, INC | $32.7M | 4.81% | 3,395,495 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX,INC | $32.1M | 4.73% | 1,750,387 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $29.9M | 4.40% | 2,201,274 | Common | SOLE |
| 45114M109 | — | Icosavax, Inc. | $28.7M | 4.23% | 3,703,704 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $28.5M | 4.20% | 3,858,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $28.3M | 4.17% | 815,724 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.4M | 4.03% | 1,989,103 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $26.3M | 3.87% | 179,917 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $20.7M | 3.04% | 2,104,875 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS, INC. | $20.3M | 2.99% | 1,142,857 | Common | SOLE |
| 75525N107 | — | RAYZEBIO, INC. | $19.3M | 2.84% | 869,908 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $14.8M | 2.18% | 1,650,150 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $13.2M | 1.94% | 2,040,816 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $13.0M | 1.91% | 1,423,642 | Common | SOLE |
| 45258J102 | IMVT | IMMUNOVANT, INC | $12.9M | 1.89% | 334,853 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $9.2M | 1.36% | 584,955 | Common | SOLE |
| 38406L103 | — | GRACELL BIOTECHNOLOGIES INC. | $8.8M | 1.29% | 3,038,889 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $7.4M | 1.09% | 486,795 | Common | SOLE |
| N5749R100 | 2GH | MERUS N.V. | $7.1M | 1.04% | 300,000 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS, INC. | $2.4M | 0.35% | 1,276,574 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.